Liminal BioSciences Inc.
Liminal BioSciences Inc. (LMNL) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
lmnl · pe ratio · data through Dec 31, 2022
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Liminal BioSciences Inc. (LMNL) measures how much investors pay for each dollar of the company's trailing earnings. LMNL's current PE ratio of N/A is calculated by dividing its stock price of $8.50 by its TTM earnings per share of -$341.80.
Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31
PE Ratio History
2003 – 2022 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Liminal BioSciences Inc.You LMNL | $28M | N/A | — | -$341.80 |
 Allakos Inc. ALLK | $30M | N/A | — | -$1.30 |
 Angion Biomedica Corp. ANGN | $30M | N/A | — | -$2.58 |
 AnPac Bio-Medical Science Co., Ltd. ANPC | $27M | N/A | — | -$54.18 |
 Freeline Therapeutics Holdings plc FRLN | $28M | N/A | — | -$22.52 |
 Opus Genetics, Inc. IRD | $330M | N/A | — | -$0.08 |
 LakeShore Biopharma Co., Ltd LSB | $26M | N/A | — | -$0.94 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2022-12-31Latest FY2022 | — | $-341.80 | — | |
2021-12-31 FY2021 | — | $-532.66 | — | |
2020-12-31 FY2020 | — | $-1443.70 | — | |
2019-12-31 FY2019 | — | $-2768.61 | — | |
2018-12-31 FY2018 | — | $-2359.49 | — | |
2017-12-31 FY2017 | — | $-1378.53 | — | |
2016-12-31 FY2016 | — | $-1684.64 | — | |
2015-12-31 FY2015 | — | $-892.74 | — | |
2014-12-31 FY2014 | 172.18x | $111.97 | — | |
2013-12-31 FY2013 | — | $-339.91 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Liminal BioSciences Inc. (LMNL) measures how much investors pay for each dollar of the company's trailing earnings. LMNL's current PE ratio of N/A is calculated by dividing its stock price of $8.50 by its TTM earnings per share of -$341.80.
Frequently asked questions
LMNL pe ratio · 6 questionsLMNL's current PE ratio is N/A as of 2026-06-09, based on a stock price of $8.50 and TTM EPS of -$341.80. Data sourced from Financial Modeling Prep via LMNL's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Liminal BioSciences Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09